SCHEMBL20520075

SCHEMBL20520075

Fc1cccc(F)c1-c1c2nc(cc3ccc([nH]3)c(-c3c(F)cccc3F)c3nc(cc4ccc1[nH]4)C=C3)C=C2

nearest known ligand 0.63

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 1/20 0.59
▸ STAT1 P42224 1/20 0.59
▸ TERT O14746 2/20 0.34
▸ CSNK1D P48730 2/20 0.32
▸ CSNK1E P49674 2/20 0.32
▸ MAPK14 Q16539 2/20 0.32
▸ DHODH Q02127 2/20 0.32
▸ TRPA1 O75762 1/20 0.32
▸ TOP1 P11387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28539046 0.90 STAT3 (0.50) STAT3STAT1TERTTOP1
SCHEMBL20520187 0.85 STAT3 (0.46) STAT3STAT1TOP1
SCHEMBL29738339 0.85 STAT3 (0.58) STAT3STAT1TERTTOP1
SCHEMBL31127549 0.84 STAT3 (0.57) STAT3STAT1TERTTOP1
SCHEMBL10482856 0.83 STAT3 (0.58) STAT3STAT1DHODHTRPA1
SCHEMBL19206150 0.83 STAT3 (0.53) STAT3STAT1TERT
SCHEMBL20843737 0.82 STAT3 (0.43) STAT3STAT1TERTDHODHTOP1
SCHEMBL30426808 0.82 STAT3 (0.56) STAT3STAT1TERTTOP1
SCHEMBL1290623 0.82 STAT3 (0.56) STAT3STAT1TERTTOP1
SCHEMBL1978627 0.82 STAT3 (0.56) STAT3STAT1TERTTOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107624114-B Low molecular weight derivatives of carboxamide halogenated porphyrins, namely chlorins and bacteriochlorins, and uses thereof 卢西蒂恩股份有限公司 2021-03-23 — — CN disclosed
US-10450322-B2 Low molecular weight derivatives of carboxamide halogenated porphyrins, namely chlorins and bacteriochlorins, and their applications thereof LUZITIN, S.A. (PT) 2019-10-22 — — US disclosed
US-10450322-B2 Low molecular weight derivatives of carboxamide halogenated porphyrins, namely chlorins and bacteriochlorins, and their applications thereof LUZITIN, S.A. (PT) 2019-10-22 — — US disclosed
EP-3292129-B1 LOW MOLECULAR WEIGHT HALOGENATED PORPHYRINE CARBOXAMIDE CHLORIN AND BACTERIOCHLORIN DERIVATIVES FOR USE IN PHOTODYNAMIC THERAPY FOR TREATING CANCER LUZITIN S A (PT) 2019-03-27 — — EP disclosed
EP-3292129-B1 LOW MOLECULAR WEIGHT HALOGENATED PORPHYRINE CARBOXAMIDE CHLORIN AND BACTERIOCHLORIN DERIVATIVES FOR USE IN PHOTODYNAMIC THERAPY FOR TREATING CANCER LUZITIN S A (PT) 2019-03-27 — — EP disclosed
US-20180282344-A1 LOW MOLECULAR WEIGHT DERIVATIVES OF CARBOXAMIDE HALOGENATED PORPHYRINS, NAMELY CHLORINS AND BACTERIOCHLORINS, AND THEIR APPLICATIONS THEREOF LUZITIN, S.A. (PT) 2018-10-04 — — US disclosed
CN-107624114-A The low-molecular-weight derivant of the porphyrin of formamide halogenation, i.e. chlorin and bacteriochlorin and its application 卢西蒂恩股份有限公司 2018-01-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450322-B2 Low molecular weight derivatives of carboxamide halogenated porphyrins, namely chlorins and bacteriochlorins, and their applications thereof CRY1, PPIA, PPOX STAT3 361/4885STAT1 833/4885TERT 1852/4885
US-20180282344-A1 LOW MOLECULAR WEIGHT DERIVATIVES OF CARBOXAMIDE HALOGENATED PORPHYRINS, NAMELY CHLORINS AND BACTERIOCHLORINS, AND THEIR APPLICATIONS THEREOF CRY1, PPIA, PPOX STAT3 361/4885STAT1 833/4885TERT 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback